Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significant Increase in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 463,100 shares, an increase of 483.2% from the January 31st total of 79,400 shares. Approximately 8.0% of the company’s stock are sold short. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is currently 0.2 days.

Bio-Path Price Performance

Shares of NASDAQ BPTH traded down $0.01 during trading hours on Friday, hitting $0.18. 72,645 shares of the stock were exchanged, compared to its average volume of 1,608,272. Bio-Path has a one year low of $0.12 and a one year high of $7.67. The company’s 50 day moving average is $0.79 and its 200 day moving average is $0.91.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Bio-Path in a research note on Saturday, February 22nd. They set a “sell” rating on the stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.